Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene score may predict prostate cancer worsening

NCT ID NCT07491406

Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 185 men with low-risk prostate cancer who chose active surveillance (monitoring instead of immediate treatment). Researchers used a genetic test called a polygenic risk score to see if it could predict which men would have their cancer get worse over time. The goal is to help doctors personalize monitoring and avoid unnecessary treatments for those at lower risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

185 people

The number who actually took part.

Started

Jan 2018

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with prostate cancer undergoing an active surveillance protocol.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of low-risk PCa (Gleason score ≤7 ) * PSA \<20 ng/mL * Clinical stage ≤T3 * Enrollment in AS with confirmatory biopsy and longitudinal follow-up * Reported family history * Signed URBAN consent * Signed protocol N. 2014 - BIOPSIE PROSTATICHE e PROSTATECTOMIE RADICALI Exclusion Criteria: * Absence of a biological sample available in the biobank. * Lack of complete clinical data related to diagnosis or follow-up during active surveillance. * Failure to perform the confirmatory biopsy required by the active surveillance protocol. * Lack of information on family history.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Genetic Risk Score prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • IRCCS San Raffaele

    Milan, IT, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.